Aveanna Healthcare (NASDAQ:AVAH) Reaches New 12-Month High - Should You Buy?

Key Points

• Aveanna Healthcare Holdings Inc. has reached a new 52-week high of $8.76, with significant trading volume of 149,266 shares.
• Several analysts have upgraded the stock's ratings, with target prices ranging from $6.00 to $9.50, reflecting a consensus rating of "Moderate Buy" with a price target of $7.92.
• Institutional investors hold a significant stake in Aveanna Healthcare, owning approximately 87.96% of the company's stock, with notable increases in their holdings from several investors in the second quarter.

Aveanna Healthcare Holdings Inc. (NASDAQ:AVAH - Get Free Report) reached a new 52-week high during trading on Friday . The company traded as high as $8.74 and last traded at $8.76, with a volume of 149266 shares traded. The stock had previously closed at $8.46.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on the company. Raymond James Financial raised Aveanna Healthcare from a "market perform" rating to an "outperform" rating and set a $9.00 price target on the stock in a research report on Monday, August 11th. Jefferies Financial Group upgraded Aveanna Healthcare from a "hold" rating to a "buy" rating and cut their target price for the company from $6.25 to $6.00 in a research note on Monday, July 21st. UBS Group upgraded Aveanna Healthcare from a "sell" rating to a "neutral" rating and boosted their target price for the company from $6.75 to $8.00 in a research note on Tuesday, August 19th. Barclays raised Aveanna Healthcare from an "equal weight" rating to an "overweight" rating and boosted their price target for the stock from $5.50 to $9.50 in a research report on Tuesday, August 19th. Finally, Wall Street Zen raised Aveanna Healthcare from a "buy" rating to a "strong-buy" rating in a report on Saturday, August 9th. Three investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $7.92.

Aveanna Healthcare Trading Up 3.3%

The firm has a market capitalization of $1.82 billion, a P/E ratio of 109.14 and a beta of 2.04. The firm has a 50-day moving average of $6.70 and a two-hundred day moving average of $5.57.

Institutional Investors Weigh In On Aveanna Healthcare

Institutional investors and hedge funds have recently made changes to their positions in the stock. Squarepoint Ops LLC grew its stake in Aveanna Healthcare by 207.0% during the second quarter. Squarepoint Ops LLC now owns 479,977 shares of the company's stock worth $2,510,000 after purchasing an additional 323,656 shares during the period. Oxford Asset Management LLP acquired a new stake in Aveanna Healthcare during the second quarter worth approximately $64,000. Lazard Asset Management LLC acquired a new stake in Aveanna Healthcare during the second quarter worth approximately $791,000. BNP Paribas Financial Markets grew its stake in Aveanna Healthcare by 1,208.6% during the second quarter. BNP Paribas Financial Markets now owns 47,215 shares of the company's stock worth $247,000 after purchasing an additional 43,607 shares during the period. Finally, Bank of America Corp DE grew its stake in Aveanna Healthcare by 172.0% during the second quarter. Bank of America Corp DE now owns 143,405 shares of the company's stock worth $750,000 after purchasing an additional 90,673 shares during the period. Institutional investors and hedge funds own 87.96% of the company's stock.

About Aveanna Healthcare

Aveanna Healthcare Holdings Inc, a diversified home care platform company, provides pediatric and adult healthcare services in the United States. Its patient-centered care delivery platform allows patients to remain in their homes and minimizes the overutilization of high-cost care settings, such as hospitals or skilled nursing facilities.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.